ten Bosch John Roderick sold $151K of BLLN

ten Bosch John Roderick (SVP of Laboratory Operations) sold 1,416 shares of BillionToOne, Inc. (BLLN) at $106.61 ($0.15M total) on 2026-09-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ten Bosch John Roderick
Published Sep 23, 2026, 9:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 9:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
high confidence
Mentioned
$BLLN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The disclosed sale represents a modest reduction in insider stake and is unlikely to affect market perception.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming dilution from future sales or secondary offerings.

Relevance 3/10Novelty 4/10Timing: Filed Sep 23 2026 (post‑market)

Background

Form 4 filings disclose insider trades; investors track them for signals of insider confidence.

Company-level read

Ticker impact

$BLLNNeutralHigh confidence
Context

Officer John Roderick sold 1,416 shares of BillionToOne for $150,959.76 via a 10b5-1 plan.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size is small relative to market cap and typical insider trading volumes.

Market effects

None; transaction is company‑specific.

None; limited to US micro‑cap market.

None

Counterpoint

Even small insider sales can signal concerns; monitor for further disposals.

Key entities

  • BillionToOne, Inc.

    US‑listed micro‑cap biotech firm (ticker BLLN).

  • John Roderick

    SVP of Laboratory Operations, officer of BillionToOne.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.